Oklahoma Health Care Authority

Drug Utilization Review Board
(DUR Board)
Meeting – May 11, 2022 @ 4:00pm
at the
Oklahoma Health Care Authority (OHCA)
4345 N. Lincoln Blvd.
Oklahoma City, Oklahoma 73105

NOTE: ***The DUR Board will meet at 4:00pm at OHCA (see address above). There will be Zoom access to this meeting; however, Zoom access will be set up in view-only mode with no voting, speaking, video, or chat box privileges. Zoom access will allow for viewing of the presentation slides as well as audio of the presentations and discussion during the meeting; however, the DUR Board meeting will not be delayed or rescheduled due to any technical issues that may arise.***

AGENDA

Discussion and action on the following items:

Items to be presented by Dr. Muchmore, Chairman:

1. **Call to Order**

A. Roll Call – Dr. Wilcox

DUR Board Members:

Dr. Stephen Anderson –	participating in person
Dr. Jennifer de los Angeles –	participating in person
Ms. Jennifer Boyett –	participating in person
Dr. Megan Hanner –	participating in person
Dr. Lynn Mitchell –	participating in person
Dr. John Muchmore –	participating in person
Dr. Lee Muñoz –	participating in person
Dr. James Osborne –	participating in person

Viewing Access Only via Zoom:

Please register for the meeting at:
https://zoom.us/webinar/register/WN_73z8ERX7Sv-KeQGP3GVqPg
After registering, you will receive a confirmation email containing information about joining the webinar.

Or join by phone:
Dial: +1-602-753-0140 or +1-669-219-2599
Webinar ID: 952 7560 1667
Passcode: 69395211

Public Comment for Meeting:

- Speakers who wish to sign up for public comment at the OHCA DUR Board meeting may do so in writing by visiting the DUR Board page on the OHCA website at www.oklahoma.gov/ohca/about/boards-and-committees/drug-utilization-review/dur-board and completing the Speaker Registration Form. Completed Speaker Registration forms should be submitted to DURPublicComment@okhca.org. Forms must be received after the DUR Board agenda has been posted and no later than 24 hours before the meeting.
- The DUR Board meeting will allow public comment and time will be limited to 40 minutes total for all speakers during the meeting. Each speaker will be given 5 minutes to speak at the public hearing. If more than 8 speakers properly request to speak, time will be divided evenly.
- Only 1 speaker per manufacturer will be allowed.
- Any speakers who sign up for public comment must attend the DUR Board meeting in person at OHCA (see above address). Public comment through Zoom will not be allowed for the DUR Board meeting.

Items to be presented by Dr. Muchmore, Chairman:

2. **Public Comment Forum**
   A. Acknowledgement of Speakers for Public Comment

Items to be presented by Dr. Muchmore, Chairman:

3. **Action Item – Approval of DUR Board Meeting Minutes – See Appendix A**
   A. April 13, 2022 DUR Board Meeting Minutes
   B. April 13, 2022 DUR Board Recommendations Memorandum

Items to be presented by Dr. Ha, Dr. Muchmore, Chairman:

4. **Update on Medication Coverage Authorization Unit/Prenatal Vitamin (PNV) Utilization Update – See Appendix B**
   A. Pharmacy Helpdesk Activity for April 2022
   B. Medication Coverage Activity for April 2022
   C. PNV Utilization Update

Items to be presented by Dr. Ha, Dr. Muchmore, Chairman:

5. **Action Item – Vote to Prior Authorize Releuko™ (Filgrastim-ayow) and Update the Approval Criteria for the Granulocyte Colony-Stimulating Factors (G-CSFs) – See Appendix C**
   A. Market News and Updates
   B. Cost Comparison for Filgrastim Products
   C. College of Pharmacy Recommendations

Items to be presented by Dr. Ha, Dr. Muchmore, Chairman:

6. **Action Item – Vote to Prior Authorize Lampit® (Nifurtimox) – See Appendix D**

A. Market News and Updates
B. Lampit® (Nifurtimox) Product Summary
C. College of Pharmacy Recommendations

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

7. **Action Item – Vote to Prior Authorize Skytrofa® (Lonapegsomatropin-tcgd) and Voxzogo™ (Vosoritide) and Update the Approval Criteria for the Growth Hormone Products – See Appendix E**

A. Market News and Updates
B. Skytrofa® (Lonapegsomatropin-tcgd) Product Summary
C. Voxzogo™ (Vosoritide) Product Summary
D. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

8. **Action Item – Vote to Prior Authorize Ponvory® (Ponesimod) and Update the Approval Criteria for the Multiple Sclerosis Medications – See Appendix F**

A. Market News and Updates
B. Ponvory® (Ponesimod) Product Summary
C. College of Pharmacy Recommendations

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

9. **Action Item – Vote to Prior Authorize Brexafemme® (Ibrexafungerp) and Update the Approval Criteria for the Systemic Antifungal Medications – See Appendix G**

A. Market News and Updates
B. Brexafemme® (Ibrexafungerp) Product Summary
C. College of Pharmacy Recommendations

Items to be presented by Dr. Borders, Dr. Muchmore, Chairman:

10. **Action Item – Vote to Prior Authorize Zynlonta™ (Loncastuximab Tesirine) and Update the Approval Criteria for the Lymphoma Medications – See Appendix H**

A. Market News and Updates
B. Zynlonta™ (Loncastuximab Tesirine) Product Summary
C. College of Pharmacy Recommendations

Items to be presented by Dr. Borders, Dr. Muchmore, Chairman:

11. **Annual Review of Lung Cancer Medications and 30-Day Notice to Prior Authorize Exkivity® (Mobocertinib), Lumakras™ (Sotorasib), and Rybrevant™ (Amivantamab-vmjw) – See Appendix I**

A. Introduction
B. Current Prior Authorization Criteria
C. Utilization of Lung Cancer Medications
D. Prior Authorization of Lung Cancer Medications

E. Market News and Updates
F. Product Summaries
G. College of Pharmacy Recommendations
H. Utilization Details of Lung Cancer Medications

Items to be presented by Dr. Borders, Dr. Muchmore, Chairman:

12. Annual Review of Ayvakit™ (Avapritinib) and Bynfezia Pen™ (Octreotide) – See Appendix J

A. Current Prior Authorization Criteria
B. Utilization of Ayvakit™ (Avapritinib) and Bynfezia Pen™ (Octreotide)
C. Prior Authorization of Ayvakit™ (Avapritinib) and Bynfezia Pen™ (Octreotide)
D. Market News and Updates
E. College of Pharmacy Recommendations
F. Utilization Details of Ayvakit™ (Avapritinib) and Bynfezia Pen™ (Octreotide)

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

13. Annual Review of Nasal Allergy Medications and 30-Day Notice to Prior Authorize Ryaltris™ (Mometasone/Olopatadine) – See Appendix K

A. Current Prior Authorization Criteria
B. Utilization of Nasal Allergy Medications
C. Prior Authorization of Nasal Allergy Medications
D. Market News and Updates
E. Ryaltris™ (Mometasone/Olopatadine) Product Summary
F. College of Pharmacy Recommendations
G. Utilization Details of Nasal Allergy Medications

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

14. Annual Review of Heart Failure (HF) Medications – See Appendix L

A. Current Prior Authorization Criteria
B. Utilization of HF Medications
C. Prior Authorization of HF Medications
D. Market News and Updates
E. College of Pharmacy Recommendations
F. Utilization Details of HF Medications

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

15. Annual Review of Anti-Diabetic Medications and 30-Day Notice to Prior Authorize Kerendia® (Finerenone), Rezvoglar™ (Insulin Glargine-aglr), and Semglee® (Insulin Glargine-yfgn) – See Appendix M

A. Current Prior Authorization Criteria
B. Utilization of Anti-Diabetic Medications
C. Prior Authorization of Anti-Diabetic Medications
D. Market News and Updates
E. Kerendia® (Finerenone) Product Summary
F. College of Pharmacy Recommendations

G. Utilization Details of Anti-Diabetic Medications

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

16. Annual Review of Muscular Dystrophy Medications – See Appendix N

A. Current Prior Authorization Criteria
B. Utilization of Muscular Dystrophy Medications
C. Prior Authorization of Muscular Dystrophy Medications
D. Market News and Updates
E. College of Pharmacy Recommendations
F. Utilization Details of Muscular Dystrophy Medications

Items to be presented by Dr. Ha, Dr. Muchmore, Chairman:

17. Annual Review of Lumizyme® (Alglucosidase Alfa) and 30-Day Notice to Prior Authorize Nexviazyme® (Avalglucosidase Alfa-ngpt) – See Appendix O

A. Current Prior Authorization Criteria
B. Utilization of Lumizyme® (Alglucosidase Alfa)
C. Prior Authorization of Lumizyme® (Alglucosidase Alfa)
D. Market News and Updates
E. Nexviazyme® (Avalglucosidase Alfa-ngpt) Product Summary
F. College of Pharmacy Recommendations

Items to be presented by Dr. Ha, Dr. Muchmore, Chairman:

18. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix P

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

19. Future Business* (Upcoming Product and Class Reviews)

A. Antiviral Medications
B. Attention-Deficit Hyperactivity Disorder (ADHD) and Narcolepsy Medications
C. Atypical Antipsychotic Medications
D. Various Special Formulations

*Future product and class reviews subject to change.

20. Adjournment

NOTE: An analysis of the atypical [Aged, Blind, and Disabled (ABD)] patient subgroup of the Oklahoma Medicaid population has been performed pertaining to all recommendations included in this DUR Board meeting packet to ensure fair and knowledgeable deliberation of the potential impact of the recommendations on this patient population.